Clinical Scorecard: Lp(a) and Women's Long-Term Heart Risk
At a Glance
| Category | Detail |
|---|---|
| Condition | Elevated Lipoprotein(a) Levels |
| Key Mechanisms | Association with increased cardiovascular risk, particularly in women with high Lp(a) levels. |
| Target Population | Healthy women, particularly of European ancestry. |
| Care Setting | Preventive medicine and cardiovascular risk assessment. |
Key Highlights
- Women with Lp(a) > 30 mg/dL have a higher 30-year risk of major cardiovascular events.
- Lp(a) levels ≥ 120 mg/dL correspond to a 54% higher risk of major cardiovascular events.
- Carriers of the rs3798220 allele have a 27% higher risk of major cardiovascular events.
Guideline-Based Recommendations
Diagnosis
- Screening for elevated Lp(a) levels in healthy patients is recommended.
Management
- Identify patients with very high Lp(a) levels for potential primary preventive efforts.
Monitoring & Follow-up
- Long-term follow-up of cardiovascular events in women with elevated Lp(a).
Risks
- Increased risk of coronary heart disease, cardiovascular death, and ischemic stroke in women with high Lp(a).
Patient & Prescribing Data
Women free of cardiovascular disease, cancer, and major chronic illness.
Potential future therapies for lowering Lp(a) levels may benefit high-risk patients.
Clinical Best Practices
- Consider genetic testing for Lp(a) elevation in women with a family history of cardiovascular disease.
- Educate patients about the implications of high Lp(a) levels on long-term heart health.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
